JohnAVestMD
Cardiology • New York, NYCardiac Electrophysiology
Assistant Professor, Medicine, Columbia University College of Phys & Surg
Are you Dr. Vest?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 91 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
New York Presbyterian Hospital
630 West 168th Street, Ph3-347
New York, NY 10032Phone+1 212-305-8194
Summary
- Dr. John Vest, MD is a cardiologist in New York, New York. He is currently licensed to practice medicine in New York. He is an Assistant Professor at Columbia University College of Phys & Surg.
Education & Training
Brigham and Women's Hospital/West Roxbury Veterans Affairs Medical CenterFellowship, Clinical Cardiac Electrophysiology, 2006 - 2007
New York Presbyterian Hospital(Cornell Campus)/Coney Island HospitalFellowship, Cardiovascular Disease, 2002 - 2006- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2002
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998
Certifications & Licensure
NY State Medical License 1999 - 2012
Clinical Trials
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Start of enrollment: 2019 Nov 26
Publications & Presentations
PubMed
- 11 citationsImpact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.Pablo Garcia-Pavia, Martha Grogan, Parag Kale, John L Berk, Mathew S Maurer
European Journal of Heart Failure. 2024-02-01 - 6 citationsEffect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study.Hannah R Rosenblum, Jan M Griffin, Masatoshi Minamisawa, Narayana Prasad, John Vest
European Journal of Heart Failure. 2023-05-01 - 1 citationsCorrection to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).Daniel P Judge, Arnt V Kristen, Martha Grogan, Mathew S Maurer, Rodney H Falk
Cardiovascular Drugs and Therapy. 2020-12-01
Press Mentions
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual MeetingJune 7th, 2021- FDA Panel Supports Patisiran for ATTR Amyloidosis with CardiomyopathySeptember 15th, 2023
